Cartilax vs Wolverine Stack (BPC-157 + TB-500)

Cartilax

Cartilax corresponds to the tripeptide Ala-Glu-Asp, one of the short peptide bioregulators studied in Russian gerontology research. The published literature names it AED or Kartalax, and PubChem lists Cartalax among the synonyms of Ala-Glu-Asp; the spelling Cartilax appears in no study located. Most of the work is cell culture from one St Petersburg group, covering skin fibroblasts, kidney explants, thymocytes and mesenchymal stem cells. The cartilage reports are three papers from that same group, published in Russian with English abstracts.

Wolverine Stack (BPC-157 + TB-500)

This blend combines two synthetic peptides, BPC-157 and TB-500, supplied together as one product; it is not a new compound. BPC-157 is a 15-residue peptide whose sequence its originators describe as derived from a protein in gastric juice; almost all of its literature comes from rodent studies, much of it from a single research group, and human data are very limited. TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ of thymosin β4, and most related research concerns the full-length 43-residue protein rather than the fragment. We are not aware of any published study that has tested the two peptides together, so the blend has no literature of its own.

How Cartilax acts

Short peptides of this class are proposed by their authors to enter the cell and act on gene expression rather than on a receptor. For AED, cell-culture reports describe changes in transcripts and proteins tied to proliferation, apoptosis and matrix turnover, including SOX9, aggrecan, type II collagen and COMP in human mesenchymal stem cells during chondrogenic differentiation. No binding partner or receptor is identified in the papers located, and the epigenetic route remains a proposal of the originating group rather than a demonstrated pathway.

How Wolverine Stack (BPC-157 + TB-500) acts

The two components are reported to act through different pathways, and no interaction between them has been studied. BPC-157 has no identified receptor; rodent and cell studies have linked it to nitric oxide signalling, to the VEGFR2 pathway in endothelial cells and to focal adhesion kinase and paxillin in cultured tendon fibroblasts. TB-500 reproduces the central actin-binding motif of thymosin β4, which in the full-length protein binds monomeric G-actin and regulates the pool of unpolymerised actin; how far the short fragment shares that binding is not well established.

The records side by side

• Type: Cartilax, Synthetic tripeptide; Wolverine Stack (BPC-157 + TB-500), Two-peptide blend
• Length: Cartilax, 3 amino acids; Wolverine Stack (BPC-157 + TB-500), not recorded
• Molecular weight: Cartilax, 333.29 g/mol; Wolverine Stack (BPC-157 + TB-500), not recorded
• Molecular formula: Cartilax, C12H19N3O8; Wolverine Stack (BPC-157 + TB-500), not recorded

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.